Abiomed Inc (ABMD)

121.07
NASDAQ : Health Care
Prev Close 121.07
Day Low/High 0.00 / 0.00
52 Wk Low/High 67.81 / 124.72
Avg Volume 592.20K
Exchange NASDAQ
Shares Outstanding 43.03M
Market Cap 5.19B
EPS 0.90
P/E Ratio 121.89
Div & Yield N.A. (N.A)

Latest News

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

'Mad Money' Lightning Round: Take Bristol-Myers Over Juno

Cramer says Abiomed is too expensive while Harman was hurt by the strong dollar.

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Jim Cramer's 'Mad Money' Recap: Why Some Stocks Pass Earnings Test and Others Fail

Johnson & Johnson was easy, Cramer says, but other stocks were more problematic.

ABIOMED Stock Sees Short Interest Fall 12.5%

ABIOMED Stock Sees Short Interest Fall 12.5%

The most recent short interest data has been released for the 06/30/2016 settlement date, which shows a 365,960 share decrease in total short interest for ABIOMED, Inc. , to 2,561,708, a decrease of 12.50% since 06/15/2016.

Abiomed (ABMD) Hits New Lifetime High

Abiomed (ABMD) Hits New Lifetime High

Trade-Ideas LLC identified Abiomed (ABMD) as a new lifetime high candidate

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Abiomed

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Breaches Of Fiduciary Duty By The Board Of Abiomed

Levi & Korsinsky announces it has commenced an investigation of Abiomed (NASDAQ: ABMD) concerning possible breaches of fiduciary duty by the board of directors of the company.

Insider Trading Alert - ABMD, POWI And AOS Traded By Insiders

Insider Trading Alert - ABMD, POWI And AOS Traded By Insiders

Stocks with insider trader activity include ABMD, POWI and AOS

2 Momentum Health Care Stocks That Will Continue to Outpace the Industry

2 Momentum Health Care Stocks That Will Continue to Outpace the Industry

If you're looking for high-velocity stocks in a low-velocity broader market, consider these little-known but fast-rising health care stars.

Abiomed Announces Q4 FY 2016 Revenue Of $94.0 Million, Up 39% Over Prior Year

Abiomed Announces Q4 FY 2016 Revenue Of $94.0 Million, Up 39% Over Prior Year

- Total Year Revenue of $329.5 Million, Up 43% Over Prior Year

Trade-Ideas: Abiomed (ABMD) Is Today's Post-Market Leader Stock

Trade-Ideas: Abiomed (ABMD) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Abiomed (ABMD) as a post-market leader candidate

Abiomed Impella® Therapy Receives FDA Approval For Cardiogenic Shock After Heart Attack Or Heart Surgery

Abiomed Impella® Therapy Receives FDA Approval For Cardiogenic Shock After Heart Attack Or Heart Surgery

Entire Family of Impella Left Side Heart Pumps FDA Approved To Enable Heart Recovery

Insider Trading Alert - PLUG, RP And ABMD Traded By Insiders

Insider Trading Alert - PLUG, RP And ABMD Traded By Insiders

Stocks with insider trader activity include PLUG, RP and ABMD

Abiomed (ABMD) Stock: Weak On High Volume Today

Abiomed (ABMD) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Abiomed (ABMD) as a weak on high relative volume candidate

Abiomed (ABMD) Is Water-Logged And Getting Wetter Today

Abiomed (ABMD) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified Abiomed (ABMD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

Today Was the Inverse of Last Year

The haves didn't have it, but there's underlying strength.

'Mad Money' Lightning Round: Take the Money and Run From Sprint

'Mad Money' Lightning Round: Take the Money and Run From Sprint

Cramer doesn't like Dunkin Brands and he's not recommending Seaspan.

Jim Cramer's 'Mad Money' Recap: More Pain Ahead, Thanks to the Fed

Jim Cramer's 'Mad Money' Recap: More Pain Ahead, Thanks to the Fed

Investors need to remain cautious and keep their cash on the sidelines, Cramer says.

Strong On High Volume: Abiomed (ABMD)

Strong On High Volume: Abiomed (ABMD)

Trade-Ideas LLC identified Abiomed (ABMD) as a strong on high relative volume candidate

Abiomed Announces Preliminary Q3 FY 2016 Revenue Of $85.8 Million, Up 38% Over Prior Year

Abiomed Announces Preliminary Q3 FY 2016 Revenue Of $85.8 Million, Up 38% Over Prior Year

U.S. Patient Utilization Grew 45%, Year Over Year

Expect Continued Swings in 2016

A decent rally could set up around the MLK holiday.